Novo Nordisk adds another obesity biotech in potential $500 deal
The transaction, worth about $16 million upfront and up to $500 million in upcoming milestones, builds upon Novo Nordisk’s collaboration with Embark Laboratories from 2018.
Lars Fruergaard Zach Gerhart Hines Inversago Pharma Metabolic Research University Of Copenhagen Novo Nordisk Foundation Center
Source: mmm-online.com